Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Trop Biomed ; 38(2): 102-110, 2021 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-34172697

RESUMEN

The use of natural products for disease control is a promising approach to solving the problem of drug resistance. The aim of the research reported here was to evaluate the fasciolicidal and anti-Clostridium novyi type B activities of propolis administered orally to sheep infected with Fasciola gigantica and C. novyi type B. Sheep infected with both pathogens were divided into two groups: an infected treated group and an infected non-treated group. The treatment was oral administration of 50 mg propolis extract/kg daily for 15 days. The body weight of the sheep, fecal egg counts of F. gigantica, serum levels of F. gigantica IgG, concentrations of cytokines (IL-2, IL-10, and IL-17), and bacterial counts of C. novyi were evaluated. Following treatment, the sheep had increased body weight and a significant decrease in the egg count, which was reduced by 54.54% at 15 days post treatment. The level of anti- Fasciola IgG increased, whereas levels of IL-2, IL-10, and IL-17 decreased in propolistreated sheep. Treatment of sheep with propolis produced a significant reduction in fecal count of C. novyi, from 8 × 109 to 3 × 103 colony units per gram at 15 days post treatment. This research highlights the therapeutic potential of Egyptian propolis extract as a treatment against F. gigantica and C. novyi type B infections, and investigated its mode of action through its effect on some cellular and humoral responses in sheep with both infections.


Asunto(s)
Infecciones por Clostridium/veterinaria , Fascioliasis , Própolis , Enfermedades de las Ovejas , Animales , Anticuerpos Antihelmínticos , Peso Corporal , Clostridium/efectos de los fármacos , Infecciones por Clostridium/tratamiento farmacológico , Fasciola/efectos de los fármacos , Fascioliasis/tratamiento farmacológico , Fascioliasis/veterinaria , Inmunoglobulina G , Interleucina-10 , Interleucina-17 , Interleucina-2 , Própolis/farmacología , Ovinos , Enfermedades de las Ovejas/tratamiento farmacológico
2.
Tropical Biomedicine ; : 102-110, 2021.
Artículo en Inglés | WPRIM | ID: wpr-904618

RESUMEN

@#The use of natural products for disease control is a promising approach to solving the problem of drug resistance. The aim of the research reported here was to evaluate the fasciolicidal and anti-Clostridium novyi type B activities of propolis administered orally to sheep infected with Fasciola gigantica and C. novyi type B. Sheep infected with both pathogens were divided into two groups: an infected treated group and an infected non-treated group. The treatment was oral administration of 50 mg propolis extract/kg daily for 15 days. The body weight of the sheep, fecal egg counts of F. gigantica, serum levels of F. gigantica IgG, concentrations of cytokines (IL-2, IL-10, and IL-17), and bacterial counts of C. novyi were evaluated. Following treatment, the sheep had increased body weight and a significant decrease in the egg count, which was reduced by 54.54% at 15 days post treatment. The level of anti- Fasciola IgG increased, whereas levels of IL-2, IL-10, and IL-17 decreased in propolistreated sheep. Treatment of sheep with propolis produced a significant reduction in fecal count of C. novyi, from 8 × 109 to 3 × 103 colony units per gram at 15 days post treatment. This research highlights the therapeutic potential of Egyptian propolis extract as a treatment against F. gigantica and C. novyi type B infections, and investigated its mode of action through its effect on some cellular and humoral responses in sheep with both infections.

3.
Int J STD AIDS ; 28(4): 362-366, 2017 03.
Artículo en Inglés | MEDLINE | ID: mdl-27178067

RESUMEN

The objective of this study was to analyse associations between sexualised substance use (chemsex), STI diagnoses and sexual behaviour among gay bisexual and other men who have sex with men accessing sexual health clinics to better inform clinical pathways. A retrospective case notes review was undertaken following the introduction of more detailed and holistic profomas for all gay bisexual and other men who have sex with men attending two London sexual health clinics between 1 June 2014 and 31 January 2015. Chemsex status was documented for 655/818. Overall, 30% disclosed recreational drug use of whom 113 (57%) disclosed chemsex and 27 (13.5%) injecting drugs. HIV-positive gay bisexual and other men who have sex with men were more likely to disclose chemsex (AOR 6.68; 95% CI 3.91-11.42; p < 0.001). Those disclosing chemsex had a higher incidence of acute bacterial STIs (AOR 2.83 CI 1.79-4.47; p < 0.001), rectal STIs (AOR 3.10 CI 1.81-5.32; p < 0.001) or hepatitis C (AOR 15.41 CI 1.50-158.17; p = 0.021). HIV incidence in the study period was 1.8% (chemsex) vs. 0.9% (no chemsex) (p = 0.61). Chemsex was associated with having more sexual partners, transactional sex, group sex, fisting, sharing sex toys, injecting drug use, higher alcohol consumption and the use of 'bareback' sexual networking applications (p < 0.004). Chemsex participants were also more likely to have accessed post-exposure prophylaxis for HIV in the study period and report sex with a discordant HIV or hepatitis C-infected partner (p < 0.001). Chemsex disclosure is associated with higher risk-taking behaviours, acute bacterial STIs, rectal STIs and hepatitis C incidence. HIV incidence was higher but not significantly so in the study period. Chemsex disclosure in sexual health clinics should prompt an opportunity for prevention, health promotion and wellbeing interventions.


Asunto(s)
Infecciones por VIH/epidemiología , Hepatitis C/epidemiología , Conducta Sexual/efectos de los fármacos , Enfermedades de Transmisión Sexual/epidemiología , Trastornos Relacionados con Sustancias/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Consumo de Bebidas Alcohólicas/epidemiología , Homosexualidad Masculina , Humanos , Londres/epidemiología , Masculino , Persona de Mediana Edad , Asunción de Riesgos , Salud Sexual , Parejas Sexuales , Minorías Sexuales y de Género , Sexo Inseguro , Adulto Joven
4.
Sex Transm Infect ; 92(8): 568-570, 2016 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-27102811

RESUMEN

OBJECTIVES: Sexualised substance use, 'chemsex', is being increasingly reported by gay, bisexual and other men who have sex with men (GBMSM) in sexual health clinics. We aim to describe the evidence base and practical ways in which clinicians can assess and advise patients disclosing chemsex. METHODS: We review published literature on chemsex, discuss vulnerability to substance use, highlight the importance of clinical communication and discuss a management approach. RESULTS: GBMSM are vulnerable to substance use problems, which interplay with mental, physical and sexual health. Knowledge on sexualised drug use and related communication skills are essential to facilitating disclosure. Identifying sexual health and other consequences of harmful drug use may motivate patients to seek change. CONCLUSIONS: Sexual health clinicians are well placed to make more holistic assessments of GBMSM accessing their services to promote broader sexual health and well-being beyond the management of HIV and sexually transmitted infections (STIs) alone.


Asunto(s)
Trastornos Relacionados con Anfetaminas/psicología , Consejo Dirigido/métodos , Reducción del Daño , Drogas Ilícitas/efectos adversos , Conducta Sexual/efectos de los fármacos , Enfermedades de Transmisión Sexual/prevención & control , Sexo Inseguro/psicología , Sexo Inseguro/estadística & datos numéricos , Trastornos Relacionados con Anfetaminas/epidemiología , Conocimientos, Actitudes y Práctica en Salud , Humanos , Masculino , Metanfetamina/efectos adversos , Parejas Sexuales/psicología , Enfermedades de Transmisión Sexual/psicología , Enfermedades de Transmisión Sexual/transmisión , Reino Unido/epidemiología
5.
Chemosphere ; 55(7): 1053-65, 2004 May.
Artículo en Inglés | MEDLINE | ID: mdl-15051374

RESUMEN

This study represents a forensic chemical analysis to define the liability for the coastal bitumens polluting the beaches of the Mediterranean city of Alexandria. Six tar balls collected from several locations along the coast of the city were analyzed for their acyclic and polycyclic hydrocarbons as well as sulfur heterocycles using GC/FID, GC/AED and gas chromatography/mass spectrometry techniques. The analysis of one Egyptian crude oil is also included as a possible source oil. The tar ball samples were at early stages of weathering. Based on the GC traces and biomarker signatures, the tar balls could be genetically different. One sample collected from the Eastern Harbor region appears to be a Bunker C type fuel produced from Egyptian crudes. The refining process has removed the low molecular weight components. On the other hand, the wide n-alkane distribution together with the absence of an unresolved complex mixture suggests that crude oils probably from tank washings, ballast discharges or accident spills from tankers could have contributed significantly to the other tar ball samples. The distribution of source specific hopane and sterane markers revealed that the tar samples probably originate from different oil fields.


Asunto(s)
Hidrocarburos Acíclicos/análisis , Hidrocarburos Cíclicos/análisis , Compuestos de Azufre/análisis , Breas/análisis , Playas , Cromatografía de Gases , Egipto , Espectrometría de Masas , Petróleo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA